Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

BDBenjamin DiamondDCDavid G. CoffeyKKK Koubek

Discussion

Loading...

Member takes

Overview

Randomized clinical trial shows improved minimal residual disease rates in NDMM with daratumumab addition, indicating enhanced response depth across cytogenetic subgroups.

Key Points

  • DKRd treatment resulted in higher minimal residual disease negativity rates, demonstrating potential clinical benefit.
  • At the second analysis cutoff, MRD negativity rates were 65% with DKRd versus 41% with KRd among gain(1q) patients.
  • This randomized clinical trial involved 306 newly diagnosed multiple myeloma patients, assessing multiple cytogenetic abnormalities.
  • Data suggests daratumumab enhances depth of response in NDMM patients across various cytogenetic subtypes.

Cite This Study

Diamond et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e00ehttps://doi.org/10.1182/blood-2025-5763
View Full Paper
Ask AI
Bookmark
Share